In terms of long-term use, both Semaglutide and Tirzepatide have been FDA-approved for chronic weight management: Semaglutide under the brand Wegovy and Tirzepatide under the brand Zepbound
Vision loss may increase or change over a few weeks but should stop progressing after two months, according to the American Academy of Ophthalmology, an association of eye physicians and surgeons
Do not recap
3 The result is reduced muscle protein mass and bone density, coupled with increased abdominal fat mass
Such decisions require careful discussion with your healthcare provider, considering your diabetes control, weight management goals, and overall side effect profile
Government programs: Medicare, Medicaid, and Tricare may cover Wegovy, but the extent of coverage varies